Windtree Therapeutics, a Nasdaq-listed biotech firm, announced plans to acquire up to $700 million in BNB, following the cryptocurrency's recent all-time high. Initially intending to purchase $200 million worth of BNB, the company now aims to raise $520 million to fund these acquisitions. It will partner with Kraken for asset custody. To finance the BNB purchases, Windtree has secured a $500 million equity line of credit with an undisclosed institutional investor and a $20 million stock-purchase agreement with Build and Build Corp. BNB, which has a market cap of approximately $106.9 billion, recently hit an all-time peak of $808 before experiencing a dip. This move aligns with other publicly traded companies diversifying their asset holdings, including a recent plan by another firm to invest $1 billion in BNB. Windtree's push into crypto comes as its stock surged by 162% over the past month, despite slipping by about 5% on the announcement day.

Source 🔗